SenoSENSE Medical Systems' Densitrode beast density sensor has received an investigational testing approval (ITA) from Health Canada.
The ITA receipt enables SenoSENSE to begin clinical testing of SenoSENSE’s proprietary Densitrode technology, which is expected to start in February 2012 at Timmins and District Hospital.
The Densitrode technology along with other breast densitometers is used to assess breast density in combination with other well-accepted breast cancer risk factors.
Mount Sinai Hospital Marvelle Koffler Breast Centre and Gattuso Rapid Diagnosis Clinic’s breast radiologist Karina Bukhanov is the principal investigator for the initial studies.
SenoSENSE Medical Systems president and CEO Joel Ironstone said the receipt of the Densitrode beast density sensor represents the first important step in advancing an exciting new technology that they believe offers great promise to identify younger women who are at increased risk of breast cancer, enable proactive intervention to reduce their risk and initiate earlier surveillance to identify cancer at an earlier and more treatable stage.